Correlation Between Gut Microbiota and Pancreatic Β-Cell Function in Diabetic Patients
NCT06645223 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2024-10-16
Summary
The gut microbiota plays a crucial role in digestion, metabolism, nutrition, and immune regulation in the human body. In recent years, numerous studies have indicated that the gut microbiota and its metabolites are closely associated with metabolic diseases, including obesity, non-alcoholic fatty liver disease, and diabetes. China has rapidly entered an aging society, where aging is a major risk factor for abnormal glucose metabolism, manifested by decreased pancreatic function and increased insulin resistance. Concurrently, as the body ages, the composition of the gut microbiota also undergoes age-related changes, such as reduced microbial diversity, increased inter-individual variability, and a downregulation of the beneficial/harmful bacteria ratio. Therefore, direct modulation of the gut microbiota could become a potential therapeutic target for age-related metabolic diseases. Currently, some preclinical studies have transplanted fecal microbiota from young mice to aged mice to explore the improvement of age-related phenotypes, such as cognitive impairment, decreased immunity, and chronic inflammation.
The regulation of the gut microbiota is susceptible to changes caused by various factors, including age, diet, antibiotics, and psychological stress. Although mice and humans share high genetic homology, differences in diet structure, body size, and metabolic processes can result in significant diversity and compositional differences in their gut microbiota. Research indicates that the core microbiota of the mouse gut consists of 4 genera, while 90% of the European population comprises 9 genera, highlighting the differences in genus or species richness between mouse and human gut microbiota. Preliminary research by our group has shown that transplanting fecal microbiota from young mice to aged mice can increase postprandial plasma insulin levels in aged mice, suggesting that the restoration of gut microbiota diversity may be involved in age-related glucose metabolism abnormalities. However, due to interspecies differences in the gut microbiota, whether the differential microbiota between elderly and young humans can improve age-related glucose metabolism abnormalities remains to be explored.
Despite the abundance of human gut microbiota composition data in public databases, differences in sequencing methods, DNA extraction from specimens, and the nationality of subjects prevent standardization and integration of these data. Additionally, traditional 16s-rRNA sequencing methods lack sufficient precision in microbial classification and cannot annotate gene functions. These limitations have resulted in many studies on gut microbiota remaining at the level of exploring correlations with diseases, without establishing causality. The development of metagenomic sequencing technology can extend the definition of the human core gut microbiota to the species level and accurately annotate their gene functions. Combined with metabolomics detection, this technology can provide more comprehensive information on the dialogue between gut microbiota and the host. Therefore, this study aims to use multi-omics approaches (metagenomic sequencing and metabolomics detection) to analyze the differences in fecal microbiota and their metabolites between young and elderly populations under different glucose metabolism states. This will provide potential intervention targets for preventing age-related glucose metabolism abnormalities and offer new theoretical foundations for the molecular mechanisms of age-related metabolic diseases.
Conditions
- Diabetes Mellitus
- Gut Microbiota
Interventions
- DRUG
-
No Interventions
no interventions
Sponsors & Collaborators
-
Peking University Third Hospital
lead OTHER
Principal Investigators
-
Yang Jin · Peking University Third Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-09-20
- Primary Completion
- 2025-12-31
- Completion
- 2026-07-01
Countries
- China
Study Locations
More Related Trials
-
A Study of Blood Metabolic Markers in Patients With Type 2 Diabetes Mellitus of Different Stages
NCT06155539 ·Status: NOT_YET_RECRUITING
-
The Alteration of Gut Microbiota and Analysis of Related Factors in Newly Diagnosed Type 2 Diabetes Patients
NCT05752851 ·Status: UNKNOWN
-
TCM and Nutrition for Diabetes Care Cohort
NCT05312450 ·Status: COMPLETED
-
Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus
NCT01902316 ·Status: COMPLETED
-
Gut Microbiota and Bile Acids in Type 2 Diabetes Mellitus
NCT04194515 ·Status: UNKNOWN
-
Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications
NCT04325126 ·Status: UNKNOWN
-
Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease
NCT06833541 ·Status: RECRUITING
-
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
NCT06682351 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
NCT04579900 ·Status: RECRUITING ·Phase: NA
-
Risk Factors for Type 2 Diabetes Mellitus With Cognitive Impairment: a Cohort Study
NCT05728567 ·Status: ACTIVE_NOT_RECRUITING
-
Glycemic Variability, Gut Microbiota, and Prognosis in T2DM With ACS
NCT06573060 ·Status: UNKNOWN
-
The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population
NCT06826729 ·Status: NOT_YET_RECRUITING
-
Phenotyping Patients With Type 2 Diabetes Mellitus and Cancer
NCT06299800 ·Status: RECRUITING
-
Tongue Fur and Metabolites in Diabetes Mellitus
NCT04909632 ·Status: COMPLETED ·Phase: NA
-
Precision Medicine of Diabetes Program in China
NCT06320600 ·Status: RECRUITING
-
HbA1c Prediction Model in Patients With Type 2 Diabetes
NCT05824286 ·Status: UNKNOWN ·Phase: NA
-
Multi-omics Mechanisms of Lifestyle Intervention in Regulating Blood Glucose
NCT07146308 ·Status: COMPLETED ·Phase: NA
-
China Diabetes Registry by Metabolic Management Center
NCT03811470 ·Status: RECRUITING
-
Cohort Study in Type 2 Diabetes in China
NCT01076023 ·Status: UNKNOWN
-
Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls
NCT06277466 ·Status: RECRUITING ·Phase: NA
-
Study of Biomarkers in Diabetic Chronic Wounds
NCT05342740 ·Status: RECRUITING
-
Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly
NCT04841668 ·Status: COMPLETED
-
Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal Study
NCT01506869 ·Status: UNKNOWN
-
Diabetes: Functional Medicine Approach Vs. Usual Care
NCT03070106 ·Status: COMPLETED ·Phase: NA
-
Research on Changes in Intestinal Barrier Function and Gut Microbiome in Patients With Type 2 Diabetes After Duodenal Mucosal Resurfacing (DMR)
NCT06385704 ·Status: NOT_YET_RECRUITING ·Phase: NA